Back to Agenda
No More Incremental Change: The Radical Future of Healthcare
Session Chair(s)
Eli Weinberg, PHD, MS
Partner
Bain & Co., United States
This closing session brings together pioneering voices at the intersection of AI, advanced computing, and biopharma to explore how a new intelligence layer is rewiring the entire life sciences value chain—from discovery to delivery. The discussion will examine how foundational AI, cloud-scale infrastructure, and digital platforms are reshaping R&D, clinical development, manufacturing, and patient engagement. The conversation will highlight not only breakthrough opportunities—smarter target discovery, more adaptive trials, real-world evidence at scale, and hyper-personalized care—but also the governance, ethics, workforce, and partnership models needed to harness these technologies responsibly in a highly regulated environment.
Learning Objective : Describe key ways AI and other advanced digital technologies are reshaping the life sciences value chain; Discuss concrete examples of how leading pharma and tech companies are using digital platforms, cloud infrastructure, and AI to accelerate R&D and improve patient outcomes; Evaluate key risks and governance challenges associated with deploying powerful AI and data technologies in regulated life sciences settings, including bias, transparency, and accountability.
Speaker(s)
Panelist
Carlos Garner, PHD, MSC
Eli Lilly and Company, United States
Senior Vice-President Global Regulatory Affairs and Head, Lilly Regenerative Med
Have an account?